|
[1]CHALASANI N, YOUNOSSI Z, LAVINE JE, et al.The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association[J].Hepatology, 2012, 55 (6) :2005-2023.
|
|
[2]LOMONACO R, SUNNY NE, BRIL F, et al.Non-alcoholic fatty liver disease:current issues and novel treatment approaches[J].Drugs, 2013, 73 (1) :1-14.
|
|
[3]LABRECQUE DR, ABBAS Z, ANANIA F, et al.World gastroenterology organisation global guidelines:nonalcoholic fatty liver disease and non-alcoholic steatohepatitis[J].J Clin Gastroenterol, 2014, 48 (6) :467-473.
|
|
[4]BREA A, PUZO J.Non-alcoholic fatty liver disease and cardiovascular risk[J].Int J Cardiol, 2013, 167 (4) :1109-1117.
|
|
[5]DONG S, LIU P, SUN MY.Role of“two-hit”in non-alcoholic fatty liver disease[J].J Clin Hepatol, 2012, 28 (7) :551-555. (in Chinese) 董姝, 刘平, 孙明瑜.非酒精性脂肪肝发病机制---“二次打击”学说研究进展[J].临床肝胆病杂志, 2012, 28 (7) :551-555.
|
|
[6]TAKAKI A, KAWAI D, YAMAMOTO K.Multiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH) [J].Int J Mol Sci, 2013, 14 (10) :20704-20728.
|
|
[7]PAOLELLA G, MANDATO C, PIERRI L, et al.Gut-liver axis and probiotics:their role in non-alcoholic fatty liver disease[J].World J Gastroenterol, 2014, 20 (42) :15518-15531.
|
|
[8]HE FP.Atherosclerosis in patients with nonalcoholic fatty liver disease[J].J Pract Hepatol, 2017, 20 (3) :263-266.何方平.非酒精性脂肪性肝病与动脉粥样硬化[J].实用肝脏病杂志, 2017, 20 (3) :263-266.
|
|
[9]TARGHER G, DAY CP, BONORA E.Risk of cardiovascular disease in patients with non-alcoholic fatty liver disease[J].N Engl JMed, 2010, 363 (3) :1341-1350.
|
|
[10]ATHYROS VG, TZIOMALOS K, KARAGIANNIS A.Statins for improving myocardial perfusion in patients with non-alcoholic fatty liver disease undergoing percutaneous coronary intervention[J].Am J Cardiol, 2016, 117 (2) :311-312.
|
|
[11]TARANTINO G, SALDALAMACCHIA G, ARENA A, et al.Non-alcoholicfatty liver disease:further expression of the metabolicsyndrome[J].J Gastroenterol Hepatol, 2007, 22 (3) :293-303.
|
|
[12]CHANG BX, ZOU ZS, LI BS, et al.2015 The Japanese Society of Gastroenterology of Evidence based clinical practice guidelines for nonalcoholic fatty live rdisease/nonal coholicsteatohepatitis[J].JClin Hepatol, 2015, 31 (7) :1027-1030. (in Chinese) 常彬霞, 邹正升, 李保森, 等.2015年日本胃肠病学会非酒精性脂肪性肝病/非酒精性脂肪性肝炎的循证医学临床治疗指南[J].临床肝胆病杂志, 2015, 31 (7) :1027-1030.
|
|
[13]Asia-Pacific Working Group.The Asia-Pacific Working Party on non-alcoholic fatty liver disease guidelines 2017[J].J Gastroenterol Hepatol, 2017.[Epub ahead of print].
|
|
[14]Group of Fatty Liver and Alcoholic Liver Diseases, Society of Hepatology, Chinese Medical Association.Guidelines for Management of non-alcoholic fatty liver disease[J].J Clin Hepatol, 2010, 26 (2) :120-124. (in Chinese) 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南[J].临床肝胆病杂志, 2010, 26 (2) :120-124.
|
|
[15]UCHIYAMA H, TSUJIMOTO M, SHINMOTO T, et al.Uremic toxins enhance statin-induced cytotoxicity in differentiated human rhabdomyosarcoma cells[J].Toxins (Basel) , 2014, 6 (9) :2612-2625.
|
|
[16]WILEY LK, MORETZ JD, DENNY JC, et al.Phenotyping adverse drug reactions:statin-related myotoxicity[J].AMIA Jt Summits Transl Sci Proc, 2015, 25 (5) :466-470.
|
|
[17]BIRTCHER K.When compliance is an issue-how to enhance statin adherence and address adverse effect[J].Curr Atheroscler Rep, 2015, 17 (1) :471.
|
|
[18]SCHULZE J, GLASS X.Statin hepatotoxicity and the dilemma of causality in rare hepatic adverse drug reactions[J].J Hepatol, 2012, 57 (3) :702-703.
|
|
[19]ABDOLI N, HEIDARI R, AZARMI Y, et al.Mechanisms of the statins cytotoxicity in freshly isolated rat hepatocytes[J].J Biochem Mol Toxicol, 2013, 27 (6) :287-294.
|
|
[20]TOLOSA L, CARMONA A, CASTELL JV, et al.High-content screening of drug-induced mitochondrial impairment in hepatic cells:effects of statins[J].Arch Toxicol, 2015, 89 (10) :1847-1860.
|
|
[21]SZABO M, VERES Z, BATAI-KONCZOS A, et al.Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin sandwich-cultured rat hepatocytes[J].Toxicol In Vitro, 2014, 28 (6) :1136-1143.
|
|
[22]GRAJALES-REYES GE, BAEZ-PAGAN CA, ZHU H, et al.Transgenic mouse model reveals an unsuspected role of the acetylcholine receptor in statin-induced neuromuscular adverse drug reactions[J].Pharmacogenomics J, 2013, 13 (4) :362-368.
|
|
[23]DORMUTH CR, FILION KB, PATERSON JM, et al.Higher potency statins and the risks of new diabetes:multicentre, observational study of administrative databases[J].BMJ, 2014, 29 (348) :g3244.
|
|
[24]SATTAR N, PREISS D, MURRAY HM, et al.Statins and risk of incident diabetes:a collaborative meta-analysis of randomised statin trials[J].Lancet, 2010, 375 (9716) :735-742.
|
|
[25]PREISS D, SESHEHASAI SR, WELSH P, et al.Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy:a meta analysis[J].JAMA, 2011, 305 (24) :2556-2564.
|
|
[26]CARTER AA, GOMES T, CAMACHO X, et al.Risk of incident diabetes among patients treated with statins:population based study[J].BMJ, 2013, 23 (346) :f2610.
|
|
[27]RIDKER PM, PRADHAN A, MACFADYEN JG, et al.Cardiovascular benefits and diabetes risks of statin therapy in primary prevention:an analysis from the JUPITER trial[J].Lancet, 2012, 380 (9841) :565-571.
|
|
[28]GOLDSTEIN LB, AMARENCO P, SZAREK M, et al.Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study[J].Neurology, 2008, 70 (24 Pt 2) :2364-2370.
|
|
[29]HYOGO H, YAMAGISHI S, MAEDA S, et al.Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property[J].Dig Liver Dis, 2012, 44 (6) :492-496.
|
|
[30]VUPPALANCHI R, CHALASANI N.Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis:selected practical issues in their evaluation and management[J].Hepatology, 2009, 49 (2) :306-317.
|
|
[31]LU YJ, CHEN ZY, YAN MX, et al.Effect of atorvastatin on adipokines in rats with nonalcoholic fatty liver disease[J].Chin J Clin Pharmacol Ther, 2015, 5 (20) :520-524. (in Chinese) 陆永娟, 陈芝芸, 严茂祥, 等.阿托伐他汀对非酒精性脂肪性肝病大鼠脂肪细胞因子的影响[J].中国临床药理学与治疗学, 2015, 20 (5) :520-524.
|
|
[32]FRAULOB JC, SOUZA-MELLO V, AGUILA MB, et al.Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers an non-alcoholic fatty liver disease in mice fed on a high-fat diet[J].Clin Sci (Lond) , 2012, 123 (4) :259-270.
|
|
[33]YOKOHAMA K, FUKUNISHI S, LI M, et al.Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice[J].Int J Mol Med, 2016, 38 (5) :1499-1506.
|
|
[34]ALKHATATBEH MJ, LINCZ LF, THORNE RF.Low simvastatin concentrations reduce oleic acid-induced steatosis in Hep G2 cells:an in vitro model of non-alcoholic fatty liver disease[J].Exp Ther Med, 2016, 11 (4) :1487-1492.
|
|
[35]SAMY W, HASSANIAN MA.Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin[J].Arab J Gastroenterol, 2011, 12 (2) :80-85.
|
|
[36]FOSTER T, BUDOFF MJ, SAAB S, et al.Atorvastatin and antioxidantsfor the treatment of nonalcoholic fatty liver disease:the St Francis Heart Study randomized clinical trial[J].Am J Gastroenterol, 2011, 106 (1) :71-77.
|
|
[37]European Association for the Study of the Liver (EASL) ;European Association for the Study of Diabetes (EASD) ;European Association for the Study of Obesity (EASO) .Clinical Practice Guidelines for themanagement of non-alcoholic fatty liver disease[J].J Hepatology, 2016, 64 (6) :1388-1402.
|
|
[38]NELSON A, TORRES DM, MORGAN AE, et al.A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis:a randomized placebo-controlled trial[J].J Clin Gastroenterol, 2009, 43 (10) :990-994.
|
|
[39]BJORNSSON ES.Hepatotoxicity of statins and other lipid-lowering agents[J].Liver Int, 2016, 37 (2) :173-178.
|
|
[40]SHI JP, FAN JG.Advances in clinical research on nonalcoholic fatty liver disease in 2009[J].J Pract Hepatol, 2010, 13 (1) :1-3. (in Chinese) 施军平, 范建高.2009年非酒精性脂肪性肝病临床研究进展回顾[J].实用肝脏病杂志, 2010, 13 (1) :1-3.
|
|
[41]CLHEN DE, ANANIA FA, CHALASANI N.An assessment of statin safety by hepatologists[J].Am J Cardiol, 2006, 97 (8) :77-81.
|
|
[42]HONG XZ, LI LD, WU LM.Effects of fenofibrate andxuezhikang on high-fat diet-induced nonalcoholic fatty liver disease[J].Clin Exp Pharmacol Physiol, 2007, 34 (2) :27-35.
|
|
[43]FABBRINI E, MOHAMMED BS, KORENBLAT KM, et al.Effect offenofibrate and niacin on intrahepatic triglyceride content, very lowdensity lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease[J].J Clin Endocrinol Metab, 2010, 95 (6) :2727-2735.
|
|
[44]FERNANDEZ-MITANDA C, PEREZ-CARREARA M, COBLINA F, et al.A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease[J].Dig Liver Dis, 2008, 40 (3) :200-205.
|
|
[45]REINER Z, CATAPANO AL, BACKER G, et al.ESC/EAS Guidelinesfor the management of dyslipidaemias:the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) [J].Eur Heart J, 2011, 32 (14) :1769-1818.
|
|
[46]BELLOSTA S, CORSINI A.Statin drug interactions and related adverse reactions[J].Expert Opin Drug Saf, 2012, 11 (6) :933-946.
|
|
[47]DESAI CS, MARTIN SS, BLUMENTHAL RS.Non-cardiovascular effects associated with statins[J].BMJ, 2014, 349:g3743.
|
|
[48]YOUNOSZAI Z, LI Z, STEPANOVA M, et al.Statin use is not associated with liver related mortality[J].Ann Hepatol, 2013, 13 (1) :84-90.
|
|
[49]DEMYEN M, ALKHALLOUFI K, PYRSOPOULOS NT.Lipidlowering agents and hepatotoxicity[J].Clin Liver Dis, 2013, 17 (4) :699-714.
|
|
[50]KIM RG, LOOMBA R, PROKOP LJ, et al.Statin use and risk of cirrhosis and related complications in patients with chronic liverdiseases:a systematic review and meta-analysis[J].Clin Gastroenterol Hepatol, 2017.[Epub ahead of print].
|
|
[51]CHATRATH H, VUPPALANCHI R, CHALASNI N.Dyslipidemia in patients with nonalcoholic fatty liver disease[J].Semin Liver Dis, 2012, 32 (1) :22-29.
|
|
[52]LIU T, ZHANG L, FAN JG, et al.An excerpt of non-alcoholic fatty liver disease (NAFLD) :assessment and management (NICEguidelines in 2016) [J].J Clin Hepatol, 2016, 32 (11) :2036-2038.
|
|
[53]SARGES P, STEINBERG JM, LEWIS JH.Drug-induced liver injury:high lights from a review of the 2015 literature[J].Drug Saf, 2016, 39 (9) :801-821.
|
|
[54]BAYS H, COHEN DE, CHALASAI N, et al.An assessment by the Statin Liver Safety Task Force:2014 update[J].J Clin Lipidol, 2014, 8 (3 Suppl) :47-57.
|
|
[55]Group for Chinese expert consensus on use of statins in elderly patients with dyslipidemia.Chinese expert consensus on use of statins in elderly patients with dyslipidemia[J].Chin J Intern Med, 2015, 54 (5) :467-477.
|
DownLoad: